Cargando…

Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study

While evidence has mounted regarding the short-term effectiveness of pharmacotherapy for opioid use disorder (OUD), little is known about longer-term psychosocial, economic, and health outcomes. We report herein 12-month outcomes for an observational study enrolling participants who had previously t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ling, Walter, Nadipelli, Vijay R., Aldridge, Arnie P., Ronquest, Naoko A., Solem, Caitlyn T., Chilcoat, Howard, Albright, Victoria, Johnson, Courtney, Learned, Susan M., Mehra, Vishaal, Heidbreder, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547872/ https://www.ncbi.nlm.nih.gov/pubmed/32187112 http://dx.doi.org/10.1097/ADM.0000000000000647

Ejemplares similares

Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study
por: Ling, Walter, et al.
Publicado: (2019)

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings
por: Boyett, Brent, et al.
Publicado: (2023)

Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment
por: Ling, Walter, et al.
Publicado: (2019)

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis
por: Andorn, Anne C., et al.
Publicado: (2020)

Patient-reported outcomes in schizophrenia patients treated with once-monthly extended-release risperidone in a long-term clinical study
por: Dhanda, Rahul, et al.
Publicado: (2019)

Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder
por: Ronquest, Naoko A, et al.
Publicado: (2018)

A Brief Educational Intervention to Increase ED Initiation of Buprenorphine for Opioid Use Disorder (OUD)
por: Khatri, Utsha G., et al.
Publicado: (2022)

Incarceration status at buprenorphine initiation and OUD treatment outcomes during pregnancy
por: Nguyen, Andrea, et al.
Publicado: (2023)

OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis
por: Wright, Nat, et al.
Publicado: (2020)

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder
por: Laffont, Celine M., et al.
Publicado: (2022)

Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs
por: Scott, Travis M., et al.
Publicado: (2021)

Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians
por: Huskamp, Haiden A., et al.
Publicado: (2023)

What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report
por: Guillou-Landreat, Morgane, et al.
Publicado: (2021)

Six-month buprenorphine-naloxone treatment is associated with neurocognitive function improvement in opioid dependence
por: Ghosh, Abhishek, et al.
Publicado: (2022)

Extended-release monthly buprenorphine injection
por: Cuperfain, Ari B., et al.
Publicado: (2023)

History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder
por: Heidbreder, Christian, et al.
Publicado: (2023)

Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system
por: Boscarino, Joseph A, et al.
Publicado: (2016)

J. J. P. Oud
por: Wiekart, K.
Publicado: (1965)

Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations
por: Neale, Joanne, et al.
Publicado: (2019)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

Monthly Patient Volumes of Buprenorphine-Waivered Clinicians in the US
por: Duncan, Alexandra, et al.
Publicado: (2020)

Correlates of Nine-Month Retention following Interim Buprenorphine-Naloxone Treatment in Opioid Dependence: A Pilot Study
por: Håkansson, A., et al.
Publicado: (2016)

An observational study on the use of long acting buprenorphine (Sublocade) and a Tamper resistant PICC for Outpatient IV antibiotic administration in Patients with serious infections and Opioid Use Disorder; The STOP OUD project
por: Pineo, Thomas, et al.
Publicado: (2021)

Afscheid van het oude normaal
por: Otto, Wim
Publicado: (2021)

Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018
por: Conway, Kevin P., et al.
Publicado: (2022)

Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder
por: Schmith, Virginia D., et al.
Publicado: (2019)

Pharmacogenomics-guided policy in opioid use disorder (OUD) management: An ethnically-diverse case-based approach()
por: Ettienne, Earl B., et al.
Publicado: (2017)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

A Prospective Three-Months Naturalistic Follow-Up Study of Outcomes of Patients with Opioid Dependence Discharged on Buprenorphine or Oral Naltrexone
por: Singh, Virendra Vikram, et al.
Publicado: (2022)

Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine
por: Abijo, Tomilowo, et al.
Publicado: (2020)

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study
por: Larance, Briony, et al.
Publicado: (2020)

Internet veertig jaar, www twintig jaar oud
Publicado: (2009)

Advances in the delivery of buprenorphine for opioid dependence
por: Rosenthal, Richard N, et al.
Publicado: (2017)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Advancing virtual primary care for people with opioid use disorder (VPC OUD): a mixed-methods study protocol
por: Hedden, Lindsay, et al.
Publicado: (2022)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

The introduction of a novel formulation of buprenorphine into organized health systems()()
por: Mullen, William, et al.
Publicado: (2022)

Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder
por: Frost, Michael, et al.
Publicado: (2019)

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial
por: Lintzeris, Nicholas, et al.
Publicado: (2021)

Internet 40 jaar en www 20 jaar oud
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ds133isnd0ecvf5ms990db6p44